Nasal MS therapy moves closer to results after final patient dosed
Study of foralumab in nonactive SPMS expected to report data this year Written by Andrea Lobo, PhD | June 30, 2026 A Phase…
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Paris, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS)…
Stuart Schlossman
CMSC 2026: Trial data show frexalimab benefits lasting 3 years
Patients with relapsing disease show stable disability levels Written by Lindsey Shapiro, PhD | June 1, 2026 Three years of treatment with Sanofi’s investigational…
Stuart Schlossman
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
· Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in…
Stuart Schlossman
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Paris, April…
Stuart Schlossman
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Press Releases April 21, 2026 South San Francisco, CA — April 21, 2026 — Genentech, a member of the Roche…
Stuart Schlossman
Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
But patients should restart treatment after 2.5 years or disease activity Written by Marisa Wexler, MS | March 17, 2026 For people with multiple…
Stuart Schlossman
Talking Biosimilars – Unlocking Patient access through coordinated action
FIRST, Click this link https://www.sandoz.com/business/biosimilars/talking-biosimilars/ to access the report. After the website page opens, CLICK the image that reads Download,,…
Stuart Schlossman
Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.
Reflections on risk, biology, and the trials progressive MS now demands Feb 03, 2026 – by: Leorah Freeman, MD, PhD…
Stuart Schlossman
Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
– FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing…
Stuart Schlossman
